Ohcanbohtosat - KRISTELEIT, REBECCA

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 Dahkki Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA Dahkki WOLFORD, JULIET E., BAI, JIARU, MOORE, KATHLEEN N., KRISTELEIT, REBECCA, MONK, BRADLEY J., TEWARI, KRISHNANSU S.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors Dahkki Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy Dahkki Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts Dahkki Chung, Yuen-Li, Troy, Helen, Kristeleit, Rebecca, Aherne, Wynne, Jackson, L Elizabeth, Atadja, Peter, Griffiths, John R, Judson, Ian R, Workman, Paul, Leach, Martin O, Beloueche-Babari, Mounia

Viečča ollesdeavstta Viečča ollesdeavstta

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials Dahkki Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies Dahkki Osborn, Gabriel, Stavraka, Chara, Adams, Rebecca, Sayasneh, Ahmad, Ghosh, Sharmistha, Montes, Ana, Lacy, Katie E, Kristeleit, Rebecca, Spicer, James, Josephs, Debra H, Arnold, James N, Karagiannis, Sophia N

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study Dahkki Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors Dahkki Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors Dahkki Brunetto, André T., Ang, Joo Ern, Lal, Rohit, Olmos, David, Molife, L. Rhoda, Kristeleit, Rebecca, Parker, Ann, Casamayor, Isabel, Olaleye, Muyibat, Mais, Anna, Hauns, Bernhard, Strobel, Vera, Hentsch, Bernd, de Bono, Johann S.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours Dahkki Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours Dahkki Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Detection of circulating tumour cell clusters in human glioblastoma Dahkki Krol, Ilona, Castro-Giner, Francesc, Maurer, Martina, Gkountela, Sofia, Szczerba, Barbara Maria, Scherrer, Ramona, Coleman, Niamh, Carreira, Suzanne, Bachmann, Felix, Anderson, Stephanie, Engelhardt, Marc, Lane, Heidi, Evans, Thomas Ronald Jeffry, Plummer, Ruth, Kristeleit, Rebecca, Lopez, Juanita, Aceto, Nicola

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment Dahkki Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... Dahkki Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors Dahkki Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A., Raynaud, Florence I., Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S., Kaye, Stan B., Derynck, Mika K., Workman, Paul, de Bono, Johann S.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten... Dahkki Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours Dahkki Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer Dahkki Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre Dahkki Russell, Beth, Moss, Charlotte, Tsotra, Eirini, Gousis, Charalampos, Josephs, Debra, Enting, Deborah, Karampera, Christina, Khan, Muhammad, Roca, Jose, Sita-Lumsden, Ailsa, Owczarczyk, Kasia, Wylie, Harriet, Haire, Anna, Smith, Daniel, Zaki, Kamarul, Swampillai, Angela, Lei, Mary, Manik, Vishal, Michalarea, Vasiliki, Kristeleit, Rebecca, Mera, Anca, Sawyer, Elinor, Flanders, Lucy, De Francesco, Irene, Papa, Sophie, Ross, Paul, Spicer, James, Dann, Bill, Jogia, Vikash, Shaunak, Nisha, Kristeleit, Hartmut, Rigg, Anne, Montes, Ana, Van Hemelrijck, Mieke, Dolly, Saoirse

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta